Repare Therapeutics Inc.
RPTX
$1.59
$0.042.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.64% | -98.90% | 4.58% | 18.19% | -58.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.64% | -98.90% | 4.58% | 18.19% | -58.79% |
| Cost of Revenue | -241.70% | -95.28% | 1.05% | -94.95% | -91.43% |
| Gross Profit | -73.52% | -99.53% | 5.82% | 186.46% | 37.28% |
| SG&A Expenses | -19.19% | -13.77% | -10.89% | -2.77% | 1.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.76% | -21.73% | -12.99% | -1.57% | 2.90% |
| Operating Income | -18.62% | -85.05% | 20.72% | 12.17% | -1,502.87% |
| Income Before Tax | -29.98% | -118.23% | 19.32% | 10.39% | -546.89% |
| Income Tax Expenses | 107.28% | 109.55% | 115.35% | -70.12% | -169.49% |
| Earnings from Continuing Operations | -60.34% | -179.90% | 9.71% | 13.73% | -2,121.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.34% | -179.90% | 9.71% | 13.73% | -2,121.82% |
| EBIT | -18.62% | -85.05% | 20.72% | 12.17% | -1,502.87% |
| EBITDA | -17.78% | -86.68% | 21.05% | 12.46% | -1,176.37% |
| EPS Basic | -59.16% | -177.18% | 10.59% | 14.41% | -2,216.14% |
| Normalized Basic EPS | -26.11% | -108.22% | 21.43% | 12.72% | -541.11% |
| EPS Diluted | -58.31% | -174.67% | 10.07% | 13.95% | -921.20% |
| Normalized Diluted EPS | -25.27% | -106.24% | 20.89% | 12.11% | -656.97% |
| Average Basic Shares Outstanding | 0.92% | 0.85% | 0.75% | 0.63% | 0.52% |
| Average Diluted Shares Outstanding | -0.14% | -0.21% | 1.82% | 1.69% | 0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |